CRISPR, Intellia and Editas
CRISPR Therapeutics (CRSP) announced revenues of Q4 2019 that beat analysts’ expectations. Based on the good news the stock market’s technicians contributed to boosting the stock’s price enabling the stock to recuperate a large part of its unwarranted recent selloff losses. New investors, who finally heard about the CRISPR gene editing technique and the Companies that specialize in it, seem to have joined CRISPR fans in buying CRISPR Therapeutics’ stock and the less expensive sisters Intellia (NTLA) and Editas (EDIT).
Prohost readers are well-informed about these CRISPR editing firms as they share a place in the Prohost Portfolio of biotech stocks. The stocks in our portfolio are picked based on their strong scientific fundamentals and their contribution to the hard to deny biotechnology revolution that is behind the clinical revolution that cannot be ignored.
CRISPR Therapeutics announcement of its 2019 Q4 financial results is indeed the reason for the current enthusiasm for this firm. The firm’s revenues and earnings have beaten by far analysts’ expectations. Its revenues generated in the quarter was $77.02 million, which is gigantic considering the fact that the firm is development-stage, having nothing yet sold.
The positive financial results are good news for sure, but that is not what we rely on when buying development-stage firms. Our enthusiasm is for the development-stage firms, and small firms, that have strong promises from their technological capabilities and investigational lead products.
With regard to CRISPR gene editing stocks our enthusiasm for the novel editing technology emanates from the fact that the FDA and other foreign regulatory agencies have given these firms the green light to conduct human clinical trials with CRISPR gene editing techniques. The regulatory agencies would not allow these techniques to be used on humans unless the serious adverse effects and all other claimed existing problems, especially, the off-target mutations, have been solved.
CRISPR Therapeutics Recent Human Clinical Trial News:
On November 19, 2019, Vertex (VRTX) and CRISPR Therapeutics announced positive, interim data from two patients treated with the CRISPR/Cas9 gene-editing therapy CTX001 in ongoing Phase 1/2 clinical trials.
A Transfusion-dependent beta-thalassemia (TDT) patient
The data for this patient reflected nine months of safety and efficacy follow-up. Before enrolling in CRISPR Therapeutics clinical study the patient required 16.5 transfusions per year (annualized rate during the two years prior to consenting for the study)
Following the gene-editing treatment the patient became transfusion independent and had total hemoglobin levels of 11.9 g/dL, 10.1 g/dL fetal hemoglobin, and 99.8% F-cells (erythrocytes expressing fetal hemoglobin).
Sickle Cell Disease Human Trial
The patient with severe sickle cell disease (SCD) received CTX001 in mid-2019 and data for this patient reflect four months of safety and efficacy follow-up.
The patient with SCD used to experience seven vaso-occlusive crises (VOCs) per year before enrolling in the clinical study. He achieved neutrophil and platelet engraftment 30 days after CTX001 infusion. None of three occurring serious adverse events (SAEs) occurred, were considered related to CTX001.
Four months after CTX001 infusion, the patient was free of vaso-occlusive crises and had total hemoglobin of 11.3 g/dL, 46.6% F hemoglobin, and 94.7% F-cells expressing F hemoglobin.
Like CRISPR Therapeutics’ enthusiasm forthe unprecedented data, the same data cemented our enthusiasm towards CRISPR Therapeutics’ future.
According to CRISPR Therapeutics the data are remarkable and demonstrate that CTX001 has the potential for being a curative gene-editing therapy for people with SCD and beta-thalassemia.
Prohost Observations
We do not believe that a fair evaluation of biotech companies could be made using technical analysis without being acquainted with the firms’ scientific fundamentals, technological capabilities and pipeline products
Biotechs Outperforming Today:
| Incyte (INCY) |
UP $2.22 |
| Seattle Genetics (SGEN) |
UP $0.83 |
| Intellia (NTLA) |
UP $0.11 |
| Editas Medicine (EDIT) |
UP $0.29 |
| CRISPR Therapeutics (CRSP) |
UP $0.94 |
| RegenxBio (RGNX) |
UP $1.04 |
| Forty Seven (FTSV) |
UP $0.73 |
| Reata (RETA) |
UP $3.96 |
We will post an article about Intellia Therapeutics and Editas Medicine soon.
To read more about these firms please use the search engine at our website.
News & Comments
February 13, 2020
CRISPR Therapeutics and Sisters
CRISPR, Intellia and Editas
CRISPR Therapeutics (CRSP) announced revenues of Q4 2019 that beat analysts’ expectations. Based on the good news the stock market’s technicians contributed to boosting the stock’s price enabling the stock to recuperate a large part of its unwarranted recent selloff losses. New investors, who finally heard about the CRISPR gene editing technique and the Companies that specialize in it, seem to have joined CRISPR fans in buying CRISPR Therapeutics’ stock and the less expensive sisters Intellia (NTLA) and Editas (EDIT).
Prohost readers are well-informed about these CRISPR editing firms as they share a place in the Prohost Portfolio of biotech stocks. The stocks in our portfolio are picked based on their strong scientific fundamentals and their contribution to the hard to deny biotechnology revolution that is behind the clinical revolution that cannot be ignored.
CRISPR Therapeutics announcement of its 2019 Q4 financial results is indeed the reason for the current enthusiasm for this firm. The firm’s revenues and earnings have beaten by far analysts’ expectations. Its revenues generated in the quarter was $77.02 million, which is gigantic considering the fact that the firm is development-stage, having nothing yet sold.
The positive financial results are good news for sure, but that is not what we rely on when buying development-stage firms. Our enthusiasm is for the development-stage firms, and small firms, that have strong promises from their technological capabilities and investigational lead products.
With regard to CRISPR gene editing stocks our enthusiasm for the novel editing technology emanates from the fact that the FDA and other foreign regulatory agencies have given these firms the green light to conduct human clinical trials with CRISPR gene editing techniques. The regulatory agencies would not allow these techniques to be used on humans unless the serious adverse effects and all other claimed existing problems, especially, the off-target mutations, have been solved.
CRISPR Therapeutics Recent Human Clinical Trial News:
On November 19, 2019, Vertex (VRTX) and CRISPR Therapeutics announced positive, interim data from two patients treated with the CRISPR/Cas9 gene-editing therapy CTX001 in ongoing Phase 1/2 clinical trials.
A Transfusion-dependent beta-thalassemia (TDT) patient
The data for this patient reflected nine months of safety and efficacy follow-up. Before enrolling in CRISPR Therapeutics clinical study the patient required 16.5 transfusions per year (annualized rate during the two years prior to consenting for the study)
Following the gene-editing treatment the patient became transfusion independent and had total hemoglobin levels of 11.9 g/dL, 10.1 g/dL fetal hemoglobin, and 99.8% F-cells (erythrocytes expressing fetal hemoglobin).
Sickle Cell Disease Human Trial
The patient with severe sickle cell disease (SCD) received CTX001 in mid-2019 and data for this patient reflect four months of safety and efficacy follow-up.
The patient with SCD used to experience seven vaso-occlusive crises (VOCs) per year before enrolling in the clinical study. He achieved neutrophil and platelet engraftment 30 days after CTX001 infusion. None of three occurring serious adverse events (SAEs) occurred, were considered related to CTX001.
Four months after CTX001 infusion, the patient was free of vaso-occlusive crises and had total hemoglobin of 11.3 g/dL, 46.6% F hemoglobin, and 94.7% F-cells expressing F hemoglobin.
Like CRISPR Therapeutics’ enthusiasm forthe unprecedented data, the same data cemented our enthusiasm towards CRISPR Therapeutics’ future.
According to CRISPR Therapeutics the data are remarkable and demonstrate that CTX001 has the potential for being a curative gene-editing therapy for people with SCD and beta-thalassemia.
Prohost Observations
We do not believe that a fair evaluation of biotech companies could be made using technical analysis without being acquainted with the firms’ scientific fundamentals, technological capabilities and pipeline products
Biotechs Outperforming Today:
We will post an article about Intellia Therapeutics and Editas Medicine soon.
To read more about these firms please use the search engine at our website.
Other Articles